Hepatocellular Carcinoma
Rajagopal N. Aravalli • Clifford J. Steer 2014 Cellular and Molecular Mechanisms and Novel Therapeutic Strategies
Continue reading →Rajagopal N. Aravalli • Clifford J. Steer 2014 Cellular and Molecular Mechanisms and Novel Therapeutic Strategies
Continue reading →Cedrik Michael Britten Sebastian Kreiter • Mustafa Diken Hans-Georg Rammensee Editors 2014 This book is a tribute to Professor Dr. Christoph Huber and his lifetime achievements. It is also a testimony to the scientific and medical progress in the growing field of immuno-oncology which is about to improve the standard of care for cancer patients. […]
Continue reading →Kathleen M. Gilbert • Sarah J. Blossom Editors 2014 This book is designed to highlight the best-characterized aspects of trichloroethylene (TCE) toxicity. These include both cancer and non-cancer endpoints. Epidemiologic data concerning the effects of TCE on human health are presented, as well as results obtained in animal models. When available, mechanistic information was provided, and future research directions […]
Continue reading →Suzanne M. Snedeker Editor 2014 Exposure and Health Risks to Consumers The purpose of this book is to provide a comprehensive resource on what is known and what we need to know about toxicants present in food packaging materials and household plastics. This includes identifying human exposure scenarios for consumers, summarizing relevant known and emerging health effects, and […]
Continue reading →Jagdish N. Sharma Editor 2014 Kinins are pharmacologically active polypeptides, which are formed in the tissues and body fluids as a result of the enzymatic action of kallikreins of kininogens. The kinin family includes bradykinin (BK) (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe- Arg), kallidin (Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), and methiony-lysyl- BK (Met-Lys-Ard-Pro-Pro-Gly-Phe-Arg). Kallidin and methionyl-lysyl-BK are converted into BK by circulation aminopeptidases in plasma and urine. BK is rapidly […]
Continue reading →Alexandre Trifilieff Editor 2014 The First Once-daily Long-acting Beta2 Agonist for COPD Chronic obstructive pulmonary disease (COPD) is a multicomponent disease (including emphysema and chronic bronchitis which may or may not coexist in the same individual) leading to a disease state characterized by poorly reversible airflow limitation that is usually progressive and associated with an abnormal inflammatory response of […]
Continue reading →Alexander A. Vinks • Hartmut Derendorf Johan W. Mouton Editors 2014
Continue reading →Jean A Klastersky 2014 Historical perspectives: why empirical therapy? The relationship between neutropenia and the risk of severe infection in patients with cancer has been clearly established early in the 1960s by Bodey et al [1]. At that time, Gram-negative bacteremia in neutropenic patients with cancer (most often with acute leukemia) carried an exceedingly high mortality of 90% […]
Continue reading →Xavier Bosch • Manuel Ramos-Casals • Munther A. Khamashta Editors 2014 Systemic autoimmune diseases are complex multisystemic illnesses whose management may involve any specialty, although the most closely involved physicians are normally rheumatologists and internists. The majority of systemic autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, primary Sjo¨gren syndrome, inflammatory myopathies, and ANCA-associated vasculitis, have […]
Continue reading →Giovanni Landoni • Laura Ruggeri Alberto Zangrillo Editors 2014 Perioperative morbidity and mortality represent a public health problem. Mortality alone is over 4 % in western countries, with striking differences among centers in the same countries and among different countries. There is initial growing awareness that drugs, techniques and strategies used in the perioperative period may influence clinical relevant […]
Continue reading →